Use of serum tumor markers for the diagnosis and follow-up of breast cancer

Oncology

Volumn 55, Issue 5, 1998, Pages 447-449

  Barrenetxea, G ^a   Schneider, J ^a   Llorente, M F ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; BREAST CANCER; FOLLOW UP; HUMAN; METASTASIS; PRIORITY JOURNAL;

EID: 0031858311     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011893     Document Type: Article

References (9)

1. Rosen P, Groshen W, Saigo P: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989;7:355-366.
2. Colomer R, Ruibal A, Genollá J, Salvador L: Circulating CA 15.3 antigen levels in non-mammary malignancies. Br J Cancer 1989;59: 283-286.
3. Pavesi F, Lotzniker M, Scarabelli M, Mauro E, Visconti G, Nicolato E: Circulating CA549 and other associated antigens in breast cancer patients. Oncology 1994;51:18-21.
4. Hayes DF, Tondini C, Kufe DW: Clinical applications of CA 15.3; in Sell (ed): Serological Cancer Markers. Totowa, Humana Press, 1992, pp 281-307.
5. Chan DW, Beveridge RA, Bhargava A, Wilcox PM, Kennedy J, Schwartz MK: Breast cancer marker CA549: A multicenter study. Immunopathology 1994;101:465-470.
6. Porter-Jordan K, Lippman ME: Overview of the biological markers of breast cancer. Hematol Oncol Clin North Am 1994;8:73-100.
7. Hayes DF: Tumor markers for breast cancer: Current utilities and future prospects. Hematol Oncol Clin North Am 1994;8:485-506.
8. Yadav GC, Rao A, Motawy MM, Safadi N, Ahmed MJ: CA 15.3 with urinary calcium excretion is useful in the diagnosis and monitoring of bone metastases from breast cancer. Int J Biol Markers 1993;8:208-214.
9. Aydiner A, Topuz E, Disci R, Yasaever V, Dincer M, Dincol K: Serum tumor markers for detection of bone metastasis in breast cancer. Acta Oncol 1994;33:181-186.